CELL INTELLIGENCE · 肿瘤细胞治疗研究

携带 BLM 突变的 DLBCL 患者在接受 CD19/CD22 双特异性 CAR-T 细胞治疗后发生继发性外周 T 细胞淋巴瘤

Secondary peripheral T-cell lymphoma in a patient with DLBCL harboring BLM mutation following CD19/CD22 bispecific CAR-T cell therapy.

复发/难治性 B 细胞非霍奇金淋巴瘤中 CD19/20 CAR-T 疗法的临床结局与空间转录组图谱

Clinical outcomes and spatial transcriptomic profiles of CD19/20 CAR-T therapy in relapsed or refractory B-cell non-Hodgkin's lymphoma.

双特异性 CD19/20 CAR-T 疗法产生了持久的临床活性，且毒性可控。

Axicabtagene ciloleucel 联合利妥昔单抗治疗难治性大 B 细胞淋巴瘤：2 期单臂 ZUMA-14 试验

Axicabtagene ciloleucel in combination with rituximab for refractory large B cell lymphoma: the phase 2, single-arm ZUMA-14 trial.

接头 CAR 共表达在淋巴瘤单一及双重抗原丢失后保留 CAR-T 细胞疗效

Co-expression of an adapter CAR retains efficacy of CAR T cells after single and dual antigen loss in lymphoma.

活细胞 Pick-Seq（LiP-Seq）：探究 CAR-T19 治疗后的超罕见套细胞淋巴瘤持续细胞

Live-cell Pick-Seq (LiP-Seq): Interrogating ultra-rare mantle cell lymphoma persistent cells after CART19 therapy.

自适应制备慢病毒抗 CD20/抗 CD19 CAR-T 细胞治疗复发/难治性套细胞淋巴瘤的 I/II 期研究

Phase I/II Study of Adaptive Manufactured Lentiviral Anti-CD20/Anti-CD19 Chimeric Antigen Receptor T Cells for Relapsed, Refractory Mantle Cell Lympho

我们证明，现场适应性生产的 LV20.19 CAR-T 细胞用于复发/难治性 MCL 是可行、安全且有效的，最佳 ORR 为 100%，安全性特征良好，迄今复发很少。

靶向 CD79b 的三种新型 CAR 用于非霍奇金淋巴瘤治疗的临床前开发及靶抗原丢失特征分析

Preclinical development of three novel CARs targeting CD79b for the treatment of non-Hodgkin's lymphoma and characterization of the loss of the target

基于特异性、疗效和靶抗原丢失，CARLY3 代表了一种针对非霍奇金淋巴瘤的潜在新型 CAR 治疗。

ARI0003：共转导 CD19/BCMA 双靶向 CAR-T 细胞治疗非霍奇金淋巴瘤

ARI0003: Co-transduced CD19/BCMA dual-targeting CAR-T cells for the treatment of non-Hodgkin lymphoma.

靶向 CD19/20 的双特异性 CAR-T 细胞治疗复发/难治性 B 细胞非霍奇金淋巴瘤患者：一项 I/II 期试验

Bispecific CAR-T cells targeting CD19/20 in patients with relapsed or refractory B cell non-Hodgkin lymphoma: a phase I/II trial.

双顺反子 CAR-T 细胞双靶向 CD19 与 CD22 治疗复发/难治性大 B 细胞淋巴瘤患者

Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphoma.